Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis

JAMA - Journal of the American Medical Association

Volumn 313, Issue 17, 2015, Pages 1736-1744

  Muir, Andrew J ^a   Poordad, Fred ^b   Lalezari, Jacob ^c   Everson, Gregory ^d   Dore, Gregory J ^e,f   Herring, Robert ^g   Sheikh, Aasim ^h   Kwo, Paul ⁱ   Hézode, Christophe ^j   Pockros, Paul J ^k   Tran, Albert ^l,m   Yozviak, Joseph ⁿ   Reau, Nancy ^o   Ramji, Alnoor ^p   Stuart, Katherine ^q   Thompson, Alexander J ^r,s   Vierling, John ^t   Freilich, Bradley ^u   Cooper, James ^v   Ghesquiere, Wayne ^p   Yang, Rong ^w   McPhee, Fiona ^w   Hughes, Eric A ^w   Swenson, E Scott ^w   Yin, Philip D ^w   more..

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c Quest Clinical Research   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f ST VINCENT S HOSPITAL   (Australia)

^g Quality Medical Research   (United States)

^h Gastrointestinal Specialists of Georgia   (United States)

ⁱ INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^k SCRIPPS CLINIC   (United States)

^l CENTRE MÉDITERRANÉEN DE MÉDECINE MOLÉCULAIRE C3M   (France)

^m UNIVERSITY HOSPITAL OF NICE   (France)

ⁿ LEHIGH VALLEY HOSPITAL   (United States)

^o UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^p UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^q GREENSLOPES PRIVATE HOSPITAL   (Australia)

^r ST VINCENT S HOSPITAL   (Australia)

^s UNIVERSITY OF MELBOURNE   (Australia)

^t BAYLOR COLLEGE OF MEDICINE   (United States)

^u Kansas City Research Institute   (United States)

^v INOVA FAIRFAX HOSPITAL   (United States)

^w BRISTOL MYERS SQUIBB   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ASUNAPREVIR PLUS BECLABUVIR PLUS DACLATASVIR; BILIRUBIN; HEMOGLOBIN; PLACEBO; RIBAVIRIN; TRIACYLGLYCEROL LIPASE; VIRUS RNA; 8-CYCLOHEXYL-N-((DIMETHYLAMINO)SULFONYL)-1,1A,2,12B-TETRAHYDRO-11-METHOXY-1A-((3-METHYL-3,8-DIAZABICYCLO(3.2.1)OCT-8-YL)CARBONYL)CYCLOPROP(D)INDOLO(2,1-A)(2)BENZAZEPINE-5-CARBOXAMIDE; ANTIVIRUS AGENT; ASUNAPREVIR; BENZAZEPINE DERIVATIVE; BMS-790052; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; ISOQUINOLINE DERIVATIVE; SULFONAMIDE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG OVERDOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENETIC VARIABILITY; GENOTYPE; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS SUBTYPE 1A; HEPATITIS C VIRUS SUBTYPE 1B; HUMAN; INSOMNIA; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIVER CIRRHOSIS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPHIL COUNT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE COUNT; TREATMENT DURATION; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; CLINICAL TRIAL; COMPLICATION; DRUG COMBINATION; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; MULTICENTER STUDY; VIROLOGY; VIRUS LOAD;

ADULT; AGED; ANTIVIRAL AGENTS; BENZAZEPINES; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; INDOLES; ISOQUINOLINES; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RIBAVIRIN; SULFONAMIDES; VIRAL LOAD;

EID: 84929208843     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.3868     Document Type: Article

References (21)

1. World Health Organization. Hepatitis C key facts. WHO factsheet no 164. April 2014. http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed October 30, 2014.
2. Di Bisceglie AM. Natural history of hepatitis C: its impact on clinical management. Hepatology. 2000;31(4):1014-1018.
3. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138(2):513-521, 521.e1-521.e6.
4. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol. 2011;9(6):509-516.e1.
5. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013;158(5 pt 1):329-337.
6. Akhtar E, Manne V, Saab S. Cirrhosis regression in hepatitis C patients with sustained virological response after antiviral therapy: a meta-analysis. Liver Int. 2015;35(1):30-36.
7. Poordad F, Bronowicki JP, Gordon SC, et al; SPRINT-2 and RESPOND-2 Investigators. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology. 2012;143(3):608-18.e1, 5.
8. Jacobson IM, Dore GJ, Foster GR, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2014;384(9941): 403-413.
9. Hézode C, Fontaine H, Dorival C, et al; CUPIC Study Group. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology. 2014;147(1):132-142.e4.
10. Bruno S, Shiffman ML, Roberts SK, et al. Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. Hepatology. 2010;51(2):388-397.
11. th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2013); November 1-5, 2013; Washington, DC.
12. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014; 370(21):1973-1982.
13. Bruno S, Vierling JM, Esteban R, et al. Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis. J Hepatol. 2013;58(3): 479-487.
14. McPhee F, Friborg J, Levine S, et al. Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir. Antimicrob Agents Chemother. 2012;56(7):3670-3681.
15. McPhee F, Falk P, Lemm J, et al. Characterization of viral escape in HCV genotype 1-infected patients treated with BMS-791325 and pegylated interferon-alfa and ribavirin [abstract]. J Hepatol. 2012;56(suppl 2):S473; doi:10.1016/S0168-8278(12)61206-9.
16. Afdhal N, Reddy KR, Nelson DR, et al; ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483-1493.
17. Afdhal N, Zeuzem S, Kwo P, et al; ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889-1898.
18. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384(9956):1756-1765.
19. Manns M, Pol S, Jacobson IM, et al; HALLMARK-DUAL Study Team. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet. 2014;384(9954):1597-1605.
20. Bronowicki JP, Ratziu V, Gadano A, et al. Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C. J Hepatol. 2014;61(6): 1220-1227.
21. Hezode C, Hirschfield GM, Ghesquiere W, et al; Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study [published online July 30, 2014]. Gut. 2014. doi:10.1136/gutjnl-2014-307498.